We thank Dr. Scarpati and Dr. Piazza for their interest and comments [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414200 | PMC |
| http://dx.doi.org/10.3390/nu14163443 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma miR-1-3p levels predict severity in hospitalized COVID-19 patients.
Br J Pharmacol
January 2025
Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy.
Ethical issues in pain and palliation.
Curr Opin Anaesthesiol
April 2024
Dipartimento di Medicina, Chirurgia, Odontoiatria 'Scuola Medica Salernitana', Università di Salerno.
Purpose Of Review: Increased public awareness of ethical issues in pain and palliative care, along with patient advocacy groups, put pressure on healthcare systems and professionals to address these concerns.Our aim is to review the ethics dilemmas concerning palliative care in ICU, artificial intelligence applications in pain therapy and palliative care, and the opioids epidemics.
Recent Findings: In this focus review, we highlighted state of the art papers that were published in the last 18 months, on ethical issues in palliative care within the ICU, artificial intelligence trajectories, and how opioids epidemics has impacted pain management practices (see Visual Abstract).
Editorial: Post COVID-19: analysing and addressing the challenges faced by patients following intensive care treatment for COVID-19.
Front Sociol
November 2023
Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy.
Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
Expert Opin Drug Discov
November 2023
Department of Medicine, Service of Infectious Diseases, Cardarelli Hospital, Naples, Italy.
Introduction: Nirmatrelvir/ritonavir (Paxlovid) represent an oral antiviral therapy approved for the treatment of COVID-19. Extensive and studies have reported the promising activity of nirmatrelvir/ritonavir against numerous emerging viruses. This combination consists of nirmatrelvir, a protease reversible inhibitor of coronavirus 3CL mainly metabolized by cytochrome P450 (CYP)3A4, and ritonavir, an inhibitor of the CYP3A isoforms that enhances the efficacy of nirmatrelvir by fixing its suboptimal pharmacokinetic properties.
View Article and Find Full Text PDFKrebs von den Lungen 6 (KL-6) levels in COVID-19 ICU patients are associated with mortality.
J Anesth Analg Crit Care
August 2022
Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana, " University of Salerno, Baronissi, SA, Italy.
Background: Krebs von den Lungen 6 (KL-6) is a high-molecular-weight mucin-like glycoprotein, which is also known as MUC1. KL-6 is mainly produced by type 2 pneumocytes and bronchial epithelial cells, and, therefore, elevated circulating KL-6 levels may denote disorders of the alveolar epithelial lining. The objective of this study is to verify if KL-6 serum level might support ICU physicians in predicting mortality, risk stratifying and triaging severe COVID-19 patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!